Oral Antibiotic Therapy of Serious Systemic Infections

Medical Clinics of North America

Volumn 90, Issue 6, 2006, Pages 1197-1222

  Cunha, Burke A ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFPROZIL; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; DOXYCYCLINE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; MOXIFLOXACIN; NAFCILLIN; OXACILLIN; PENICILLIN G; TELITHROMYCIN; TOBRAMYCIN; UNINDEXED DRUG;

ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CRITICAL ILLNESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; FEBRILE NEUTROPENIA; HUMAN; INTERMETHOD COMPARISON; INTESTINE ABSORPTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; ORAL ANTIBIOTIC THERAPY; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL AVAILABILITY; COMMUNITY-ACQUIRED INFECTIONS; ENDOCARDITIS, BACTERIAL; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL ABSORPTION; METHICILLIN RESISTANCE; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; STAPHYLOCOCCAL INFECTIONS;

EID: 33751001589     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2006.07.009     Document Type: Review

References (110)

1. In: Kucers A., Crowe S.M., Grayson M.L., et al. (Eds). The use of antibiotics. 5th edition (1997), Butterworth-Heinemann, Oxford
2. In: Bryskier A. (Ed). Antimicrobial agents (2005), ASM Press, Washington (DC)
3. In: O'Grady F., Lambert H.P., Finch R.G., et al. (Eds). Antibiotics and chemotherapy. 2nd edition (1997), Churchill Livingstone, New York
4. Cunha B.A. Intravenous to oral antibiotic switch therapy. Drugs Today 37 (2001) 311-319
5. McCue J.D. Oral antibiotics practical prescribing rules for practitioners. Geriatrics 47 (1992) 59-66
6. In: Cunha B.A. (Ed). Antibiotic essentials. 5th edition (2006), Physicians' Press, Royal Oak (MI)
7. Altemeier W.A., Culbertson W.R., and Coith R.L. The intestinal absorption of oral antibiotics in traumatic shock; an experimental study. Surg Gynecol Obstet 92 (1951) 707-711
8. Power B.M., Forbes A.M., van Heerden P.V., et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 34 (1998) 25-56
9. Fish D.N., and Abraham E. Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients. Antimicrob Agents Chemother 43 (1999) 1277-1280
10. Karjagin J., Pähkla R., Karki T., et al. Distribution of metronidazole in muscle tissue of patients with septic shock and its efficacy against Bacteroides fragilis in vitro. J Antimicrob Chemother 55 (2005) 341-346
11. Plaisance K.I., Quintiliani R., and Nightingale C.H. The pharmacokinetics of metronidazole and its metabolites in critically ill patients. J Antimicrob Chemother 21 (1988) 195-200
12. Schrenzel J., Cerruti F., Herrmann M., et al. Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. Antimicrob Agents Chemother 38 (1994) 1219-1224
13. Rebuck J.A., Fish D.N., and Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22 (2002) 1216-1225
14. Pea F., and Furlanut M. Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients. J Chemother 16 Suppl 2 (2004) 8-10
15. Sultan E., Richard C., Pezzano M., et al. Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. Eur J Clin Pharmacol 34 (1988) 637-643
16. Sensakovic J.W., and Smith L.G. Oral antibiotic treatment of infectious diseases. Med Clin North Am 85 (2001) 115-123
17. Quintiliani R., and Nightingale C.H. Transitional antibiotic therapy. Infect Dis Clin Practice 3 Suppl (1994) 161-167
18. Siegel R.E., Halpern N.A., Almenoff P.L., et al. A prospective randomized study of inpatient intravenous antibiotics for community-acquired pneumonia: the optimal duration of therapy. Chest 110 (1996) 965-971
19. Borg R., Dotevall L., Hagberg L., et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis 37 (2005) 449-454
20. Cunha B.A. Minocycline vs. doxycycline for the antimicrobial therapy of Lyme neuroborreliosis. Clin Infect Dis 30 (2000) 237-238
21. Bryskier A. Bacillus anthracis and antibacterial agents. Clin Microbiol Infect 8 (2002) 467-478
22. Boulanger L.L., Ettestad P., Fogarty J.D., et al. Gentamicin and tetracyclines for the treatment of human plague review of 75 cases in New Mexico, 1985-1999. Clin Infect Dis 38 (2004) 663-669
23. Mwengee W., Butler T., Mgema S., et al. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis 42 (2006) 614-621
24. Lyamuya E.F., Nyanda P., Mohammedali H., et al. Laboratory studies on Yersinia pestis during the 1991 outbreak of plague in Lushoto, Tanzania. J Trop Med Hyg 95 (1992) 335-338
25. Ratsitorahina M., Chanteau S., Rahalison L., et al. Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar. Lancet 355 (2000) 111-113
26. Solera J., Geijo P., Largo J., et al. A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis. Clin Infect Dis 39 (2004) 1776-1782
27. Newton P.N., Chaulet J.F., Brockman A., et al. Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria. Antimicrob Agents Chemother 49 (2005) 1622-1625
28. Clemett D., and Markham A. Linezolid. Drugs 59 (2000) 815-827
29. Jonas M., and Cunha B.A. Minocycline. Ther Drug Monit 4 (1982) 137-145
30. Marchetti F., and Viale P. Current and future perspectives for levofloxacin in severe Pseudomonas aeruginosa infections. J Antimicrob Chemother 15 (2003) 315-322
31. Nightingale C.H., Grant E.M., and Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 46 (2000) 6-14
32. Bucaneve G., Micozzi A., Menichetti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353 (2005) 977-987
33. Cunha B.A. Community-acquired pneumonias: reality revisited. Am J Med 108 (2000) 436-437
34. Cunha B.A. Severe community-acquired pneumonia. J Crit Illn 12 (1997) 711-721
35. Cunha B.A. Severe community-acquired pneumonia. Crit Care Clin 8 (1998) 105-117
36. Cunha B.A. Antibiotic treatment of severe community-acquired pneumonia. Semin Respir Crit Care Med 21 (2000) 61-69
37. Cunha B.A. Severe community-acquired pneumonia: determinants of severity and approach to therapy. Infect Med 22 (2005) 53-58
38. Cunha B.A. Oral or intravenous-to-oral antibiotic switch therapy for treating patients with community-acquired pneumonia. Am J Med 111 (2001) 412-413
39. Ramirez J.A., and Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 161 (2001) 848-850
40. Furlanut M., Brollo L., Lugatti E., et al. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 51 (2003) 101-106
41. Dunbar L.M., Wunderink R.G., Habib M.P., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 37 (2003) 752-760
42. File Jr. T.M., Milkovich G., Tennenberg A.M., et al. Clinical implications of 750 mg 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin 20 (2004) 1473-1481
43. Marrie T.J., Lau C.Y., Wheeler S.L., et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 283 (2000) 749-755
44. Hoefken G., Talan D., Larsen L.S., et al. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis 23 (2004) 772-775
45. Katz E., Larsen L.S., Fogarty C.M., et al. Safety and efficacy of sequential IV to PO moxifloxacin versus conventional combination therapies in the treatment of community-acquired pneumonia in patients requiring initial IV therapy. J Emerg Med 27 (2004) 554-559
46. Lode H., Grossman C., Choudhri S., et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med 97 (2003) 1134-1142
47. Rijnders B.J. Moxifloxacin for community-acquired pneumonia. Antimicrob Agents Chemother 47 (2003) 444-445
48. Torres A., Muir J.F., Corris P., et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia in community-acquired pneumonia. Eur Respir J 21 (2003) 135-143
49. Shea K.W., Ueno Y., Abumustafa F., et al. Doxycycline activity against Streptococcus pneumoniae. Chest 107 (1995) 1775-1776
50. Lederman E.R., Gleeson T.D., Driscoll T., et al. Doxycycline sensitivity of S. pneumoniae isolates. Clin Infect Dis 36 (2003) 1091
51. Jones R.N., Sader H.S., and Fritsche T.R. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). Diagn Microbiol Infect Dis 49 (2004) 147-149
52. Johnson J.R. Doxycycline for treatment of community-acquired pneumonia. Clin Infect Dis 35 (2002) 632-633
53. Cunha B.A. Doxycycline re-visited. Arch Intern Med 159 (1999) 1006-1007
54. Cunha B.A. Doxycycline for community-acquired pneumonia. Clin Infect Dis 37 (2003) 870
55. Carbon C., Moola S., Velancsics I., et al. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin Microbiol Infect 9 (2003) 691-703
56. Hagberg L., Torres A., van Rensburg D., et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 30 (2002) 378-386
57. Ortega M., Marco F., Almela M., et al. Activity of telithromycin against erythromycin-susceptible and resistant Streptococcus pneumoniae is from adults with invasive infections. Int J Antimicrob Agents 24 (2004) 616-618
58. Pullman J., Champlin J., and Vrooman P.S. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 57 (2003) 377-384
59. Tellier G., Niederman M.S., Nusrat R., et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10-day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 54 (2004) 515-523
60. Reinert R.R. Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother 53 (2004) 918-927
61. van Rensburg D.J., Fogarty C., Kohno S., et al. Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin. Chemotherapy 51 (2005) 186-192
62. Carbon C., and Nusrat R. Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila. Eur J Clin Microbiol Infect Dis 23 (2004) 650-652
63. Low D.E., Felmingham D., Brown S.D., et al. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. J Infect 49 (2004) 115-125
64. Klugman K.P., and Lonks J.R. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 11 (2005) 802-807
65. Pihlajamaki M., Kotilainen P., Kaurila T., et al. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 33 (2001) 483-488
66. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35 (2002) 556-564
67. Rzeszutek M., Wierzbowski A., Hoban D.J., et al. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int J Antimicrob Agents 24 (2004) 95-104
68. Cunha B.A. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?. Chest 125 (2004) 1913-1919
69. Cunha B.A. Empiric oral monotherapy for hospitalized patients with community-acquired pneumonia: an idea whose time has come. Eur J Clin Microbiol Infect Dis 23 (2004) 78-81
70. Cunha B.A. Nosocomial pneumonia. Diagnostic and therapeutic considerations. Med Clin North Am 85 (2001) 79-114
71. Bartlett J.G., O'Keefe P., Tally F., et al. Bacteriology of hospital-acquired pneumonia. Arch Intern Med 146 (1986) 868-871
72. Bonten M.J.M., and Bergmans D.C.J.J. Nosocomial pneumonia. In: Mayhall C.G. (Ed). Hospital epidemiology and infection control. 2nd edition (1999), Lippincott Williams & Wilkins, Philadelphia (PA)
73. Bonten M.J.M., Gaillard C.A., Wouters E.F., et al. Problems in diagnosing nosocomial pneumonia in mechanically ventilated patients: a review. Crit Care Med 22 (1994) 1683-1691
74. Cunha B.A. Fever in the intensive care unit. Intensive Care Med 25 (1999) 648-651
75. Meduri G.U., Mauldin G.L., Wunderink R.G., et al. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest 106 (1994) 221-235
76. Francis J.S., Doherty M.C., Lopatin U., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40 (2005) 100-107
77. Gillet Y., Issartel B., Vanhems P., et al. Association between Staphylococcus aureus strains carrying genes for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 359 (2002) 753-759
78. Padmanabhan R.A., and Fraser T.C. The emergence of methicillin-resistant Staphylococcus aureus in the community. Cleve Clin J Med 72 (2005) 235-241
79. Chini V., Petinaki E., Foka A., et al. Spread of Staphylococcus aureus clinical isolates carrying Panton-Valentine leukocidin genes during a 3-year period in Greece. Clin Microbiol Infect 12 (2006) 29-34
80. Alonso-Tarrés C., Villegas M.L., de Gispert F.J., et al. Favorable outcome of pneumonia due to Panton-Valentine leukocidin-producing Staphylococcus aureus associated with hematogenous origin and absence of flu-like illness. Eur J Clin Microbiol Infect Dis 24 (2005) 756-759
81. Diederen B.M.W., and Kluytmans J.A.J.W. The emergence of infections with community-associated methicillin-resistant Staphylococcus aureus. J Infect 52 (2006) 157-168
82. Kluytmans-VandenBergh M.F.Q., and Kluytmans J.A.J.W. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infect 12 Suppl 1 (2006) 9-15
83. Cunha B.A. Ventilator-associated pneumonia: monotherapy is optimal if chosen wisely. Crit Care 10 (2006) 141
84. Weinstein L., and Brusch J.L. Infective endocarditis (1966), Oxford University Press, New York
85. Kaye D. Infective endocarditis. 2nd edition (1992), Raven Press, New York
86. Barry J., and Gump D.W. Endocarditis: an overview. Heart Lung 11 (1982) 137-145
87. Levine D.P., Holley H.P., Eiseman I., et al. Clinafloxacin for the treatment of bacterial endocarditis. Clin Infect Dis 38 (2004) 620-631
88. Ng K.H., Lee S., Yip S.F., et al. A case of Streptococcus mitis endocarditis successfully treated by linezolid. Hong Kong Med J 11 (2005) 411-413
89. Ravidran V., John J., Kaye G.C., et al. Successful use of oral linezolid as a single active agent in endocarditis unresponsive to conventional antibiotic therapy. J Infect 47 (2003) 164-166
90. Cunha B.A., Gill M.V., and Lazar J.M. Acute infective endocarditis. Infect Dis Clin North Am 10 (1996) 811-834
91. Yuk J.H., Dignani M.C., Harris R.L., et al. Minocycline as an alternative antistaphylococcal agent. Rev Infect Dis 13 (1991) 1023
92. Steinberg P.J., Clark C.C., and Hickman B.O. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 23 (1996) 255-259
93. Mounzer K.C., and DiNubile M.J. Clinical presentation and management of methicillin-resistant Staphylococcus aureus (MRSA) infections. Antibiot Clin 2 (1998) 15-20
94. Paradisi F., Corti G., and Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 85 (2001) 1-17
95. Cunha B.A. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11 Suppl 4 (2005) 33-42
96. Cunha B.A. Oral antibiotics to treat MRSA infections. J Hosp Infect 60 (2005) 88-90
97. Clumeck N., Marcelis L., Amiri-Lamraski M.H., et al. Treatment of severe staphylococcal infections with rifampin-minocycline association. J Antimicrob Chemother 13 (1984) 71-72
98. Kuwabara K., Shigeoka H., Ontonari T., et al. Successful treatment with minocycline of 2 cases of endocarditis caused by staphylococcus. Chemotherapy (Tokyo) 33 (1985) 904
99. Lawler M.T., Sullivan M.C., Levitz R.E., et al. Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis 161 (1990) 812-814
100. Levine D.P., Cushing R.D., Jui J., et al. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 97 (1982) 330-338
101. Lewis S., and Lewis B. Minocycline therapy of resistant Staphylococcus aureus infections. Infect Control Hosp Epidemiol 14 (1993) 423
102. Safdar A., Bryan C.S., Stinson S., et al. Prosthetic valve endocarditis due to vancomycin-resistant Enterococcus faecium: treatment with chloramphenicol plus minocycline. Clin Infect Dis 34 (2002) E61-E63
103. de Feiter P.W., Jacobs J.A., Jacobs J.H.M., et al. Successful treatment of Staphylococcus epidermidis prosthetic valve endocarditis with linezolid after failure of treatment with oxacillin, gentamicin, rifampicin, vancomycin, and fusidic acid regimens. Scan J Infect Dis 37 (2005) 173-176
104. Hill E.E., Herijgers P., Herregods M.-C., et al. Infective endocarditis treated with linezolid: case report and literature review. Eur J Clin Microbiol Infect Dis 25 (2006) 202-204
105. Stevens D.L., Herr D., Lampiris H., et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcal aureus infections. Clin Infect Dis 34 (2002) 1481-1490
106. Babcock H.M., Ritchie D.J., Christiansen E., et al. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 32 (2001) 1373-1375
107. Park D., Pugliese A., and Cunha B.A. Legionella micdadei prosthetic valve endocarditis. Infection 22 (1994) 213-215
108. Rolain J.M., Boulos A., Mallet M.N., et al. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother 49 (2005) 2673-2676
109. Rolain J.M., Mallet M.N., and Raoult D. Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis. J Infect Dis 188 (2003) 1322-1325
110. Tompkins L.S., Roessler B.J., Redd S.C., et al. Legionella prosthetic-valve endocarditis. N Engl J Med 318 (1988) 530-535